業績

HOME > 業績

論文・学会発表

2016年

論文発表

  • Yang J, Sequist L, Zhou C, Schuler M, Geater S, Mok T, Hu C, Yamamoto N, Feng J, O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Marten A, Massey D, Wind S, Wu Y.
  • Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post-hoc analyses of the randomized LUX-Lung 3 and 6 trials.
  • Annals of Oncology 27(11): 2103-10
  • Yamada K, Azuma K, Takeshita M, Uchino J, Nishida C, Suetsugu T, Kondo A, Harada T, Eida H, Kishimoto J, Eriguchi G, Takayama K, Nakanishi Y, Sugio K.
  • Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
  • Anticancer Res 36(6): 2881-7
  • Swain A, Kulkeaw K, Tanaka Y, Nakanishi Y, Shirasawa S, Sugiyama D.
  • DBA Lectin Binds to Highly Proliferative Mouse Erythroleukemia Cells.
  • Anticancer Res 36(7): 3625-33
  • Koide R, Kulkeaw K, Tanaka Y, Swain A, Nakanishi Y, Sugiyama D.
  • Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes the Expansion of Human Promyelocytic Leukemia Cell Line, NB4.
  • Anticancer Res 36(7): 3635-43
  • Kakino K, Kiyohara C, Horiuchi T, Nakanishi Y.
  • CYP2E1 rs2031920, COMT rs4680 Polymorphisms, Cigarette Smoking, Alcohol Use and Lung Cancer Risk in a Japanese Population.
  • Asian Pac J Cancer Prev 17(8): 4063-70
  • Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I.
  • Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
  • Cancer 122(7): 1050-9
  • Takahashi H, Shimodaira S, Ogasawara M, Ota S, Kobayashi M, Abe H, Morita Y, Nagai K, Tsujitani S, Okamoto M, Suzuki Y, Nakanishi Y, Yonemitsu Y; DC Vaccine Study Group at the Japanese Society of Immunotherapy and Cell Therapy.
  • Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis.
  • Cancer Immunol Immunother 65(9): 1099-111
  • Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, Park JH, Nakamura Y, Ihn H.
  • Myasthenic crisis and polymyositis induced by one dose of nivolumab.
  • Cancer Science 107(7): 1055-8
  • Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.
  • FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
  • Cancer Science 107(11): 1667-76
  • Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, Marumoto T, Takahashi A, Okazaki T, Takeda K, Hirakawa M, Fujii H, Okano S, Morita M, Baba E, Mizumoto K, Maehara Y, Tanaka M, Akashi K, Nakanishi Y, Yoshida K, Tsunoda T, Tamura K, Nakamura Y, Tani K.
  • Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
  • Clinical Immunology 166-7: 48-58
  • Kawakami H, Okamoto I.
  • MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
  • Gastric Cancer 19(3): 687-95
  • Katahira K, Ogura Y, Gotoh Y, Hayashi T.
  • Draft Genome Sequences of Five Rapidly Growing Mycobacterium Species: M. thermoresistibil, M. fortuitum subsp. acetamidolyticum, M. canariasens, M. brisbanense and M. novocastrense.
  • Genome Announcements 4(3): e00322-16
  • Fujita M, Ouchi H, Ikegame S, Harada E, Matsumoto T, Uchino J, Nakanishi Y, Watanabe K.
  • Critical role of tumor necrosis factor receptor 1 in the pathogenesis of pulmonary emphysema in mice.
  • Int J Chron Obstruct Pulmon Dis 11: 1705-12
  • Tsukuya G, Samukawa T, Matsumoto K, Fukuyama S, Kumamoto T, Uchida A, Koriyama C, Ninomiya T, Inoue H.
  • Comparison of the COPD Population Screener and International Primary Care Airway Group questionnaires in a general Japanese population: the Hisayama study.
  • Int J Chron Obstruct Pulmon Dis 11: 1903-9
  • Kajiwara M, Ban T, Matsubara K, Nakanishi Y, Masuda S.
  • Urinary Dopamine as a Potential Index of the Transport Activity of Multidrug and Toxin Extrusion in the Kidney.
  • Int J Mol Sci 17(8): 1228
  • Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y.
  • Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
  • J Clin Oncol 34(27): 3248-57
  • Takayama K, Sugawara S, Saijo Y, Maemondo M, Sato A, Takamori S, Harada T, Sasada T, Kakuma T, Kishimoto J, Yamada A, Noguchi M, Itoh K, Nakanishi Y.
  • Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
  • J Immunol Res 2016: 1745108
  • Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y.
  • Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae.
  • J Thorac Oncol 11(9): 1586-90
  • Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M
  • Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
  • Japanese Journal of Clinical Oncology 46(5): 462-7
  • Yan Li, Kyosuke Kobayashi, Marwa Mohamed Mona, Chikako Satomi, Shinji Okano, Hiroyuki Inoue, Kenzaburo Tani, Atsushi Takahashi.
  • Immunogenic FEAT protein circulates in the bloodstream of cancer patients.
  • Journal of Translational Medicine 14(1): 275
  • Sakata S, Saekia S, Okamoto I, Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishie H, Hirosako S, Yamaguchi E, Aragane N, Fujii S, Harada T, Iwama E, Semba H, Nakanishi Y, Kohrogi H.
  • Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
  • Lung Cancer 99: 41-5
  • Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Janne P, Nakagawa K
  • Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
  • Oncogene 35(7): 878-86
  • Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.
  • HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
  • Oncotarget 7(3): 3453-60
  • Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH.
  • Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
  • Oncotarget 7(12): 13621-33
  • Inoue H, Kato T, Olugbile S, Tamura K, Chung S, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y, Park JH.
  • Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
  • Oncotarget 7(14): 17652-64
  • Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K.
  • Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
  • Oncotarget 7(36): 58492-9
  • Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, Katakami N, Sakamoto K, Yamashita Y, Okami J, Mitsudomi T, Yamashita M, Yokouchi H, Okubo K, Okada M, Takenoyama M, Chida M, Tomii K, Matsuura M, Azuma A, Iwasawa T, Kuwano K, Sakai S, Hiroshima K, Fukuoka J, Yoshimura K, Tada H, Nakagawa K, Nakanishi Y; West Japan Oncology Group.
  • A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
  • Respir Res 17(1): 90
  • Yoshida Y, Nagata N, Tsuruta N, Kitasato Y, Wakamatsu K, Yoshimi M, Ishii H, Hirota T, Hamada N, Fujita M, Nabeshima K, Kiyomi F, Watanabe K.
  • Heterogeneous clinical features in patients with pulmonary fibrosis showing histology of pleuroparenchymal fibroelastosis.
  • Respiratory Investigation 54(3): 162-9
  • Ishii Y, Saeki K, Liu M, Sasaki F, Koga T, Kitajima K, Meno C, Okuno T, Yokomizo T.
  • Leukotriene B4 receptor type 2 (BLT2) enhances skin barrier function by regulating tight junction proteins.
  • The FASEB Journal 30(2): 933-47
  • Fukuyama S, Matsumoto K, Kaneko Y, Kan-O K, Noda N, Tajiri-Asai Y, Nakano T, Ishii Y, Kiyohara Y, Nakanishi Y, Inoue H; Hisayama Pulmonary Physiology Study Group.
  • Prevalence of Airflow Limitation Defined by Pre- and Post-Bronchodilator Spirometry in a Community-Based Health Checkup: The Hisayama Study.
  • Tohoku J Exp Med 238(2): 179-84
  • Kotetu Y, Ikegame S, Takebe-Akaswasa K. Koga T, Okabayashi K, Takata S.
  • A Case of lgG4-related Lung Disease Complicated by Asymptomatic Chronic Epstein-Barr Virus lnfection.
  • Clin Respir J: Epub ahead of print (Jan 25)
  • Mine Y, Munir H, Nakanishi Y, Sugiyama D.
  • Biomimetic Peptides for the Treatment of Cancer.
  • Anticancer Res 36(7): 3565-70
  • 緒方彩子、濵田直樹、三雲大功、鈴木邦裕、髙山浩一、中西洋一
  • 当科における気管支肺胞洗浄の合併症の検討
  • 気管支学 38(3): 173-8
  • 鈴木利繁、道傅研司、保田尚邦、中西洋一、伊藤 実、山岡延樹、三原基弘、長嶋浩貴、中村紘一、清水義博、降旗謙一、木曽達也、上野眞義、嶋田 顕、大西明弘
  • エスエーワンR配合OD錠T25の癌患者における生物学的同等性試験
  • 診療と新薬 53(7): 574-663
  • 江内田寛、平形明人、大路正人、西田幸二、久保田敏昭、緒方奈保子、園田康平、内山麻希子、岸本淳司、戸高浩二、中西洋一、石橋達朗
  • A0001(ブリリアントブルーG250)の内境界膜染色と剥離に対する有効性と安全性の検討-多施設共同第III相医師主導治験
  • 日本眼科学会雑誌 120: 39-448
  • 緒方大聡、今永知俊、田原正浩、森脇篤史
  • 関節リウマチの治療中に合併した播種性ノカルジア症の1例
  • 日本呼吸器学会誌 5(1): 32-6
  • 緒方大聡、今永知俊、田原正浩、森脇篤史
  • 肺カンサシ症の治療中にムコール症を合併した1例
  • 日本呼吸器学会誌 5(3): 154-7
  • 有村雅子、河口知允、伊地知佳世、中島 豊、継 仁、出水みいる
  • PDF先端巨大症にEGFR遺伝子変異陽性肺癌を合併した1例
  • 日本呼吸器学会誌: Epub ahead of print (Aug 16)
  • 片平雄之、濵田直樹、山本悠造、緒方彩子、松元幸一郎、中西洋一
  • PDF間質性肺疾患が疑われた重症呼吸不全に対して体外式膜型人工肺を使用し救命できた1例
  • 日本呼吸器学会誌: Epub ahead of print (Aug 29)
  • 片平雄之、西原智恵、野上裕子、岩永知秋
  • 呼吸器カンファレンス Pulmonary grand round-第31回うふいち会呼吸器症例検討会-悪性リンパ腫化学療法後に呼吸不全が進行した1例
  • Progress in Medicine 36(1): 141-8
  • 鈴木邦裕、濵田直樹、大坪孝平、緒方彩子、原田英治、小田義直、中西洋一
  • 特発性肺線維症を基礎疾患として急激な呼吸状態の悪化をきたした1例
  • THE LUNG Perspective 24(1): 4-9
  • 田中謙太郎、岡本 勇
  • 特集/呼吸器病学TOPICS 2015-16 7.腫瘍「免疫チェックポイント抗体による肺癌の治療」
  • 分子呼吸器病 20(1): 52-5
  • 田中謙太郎、髙田昇平
  • 進行期扁平上皮NSCLCに対する,ニボルマブとドセタキセルの比較第III相臨床試験
  • がん分子標的治療 14(1): 148-52
  • 藤平智道、岡本 勇、中西洋一
  • 非小細胞肺癌の化学療法のトピックス
  • 成人病と生活習慣病 46(4): 461-5
  • 田中謙太郎、岡本 勇
  • 免疫チェックポイント抗体による肺癌の治療
  • 分子呼吸器病 20(1): 52-5
  • 田中謙太郎、岡本 勇
  • 免疫療法が肺がん治療に与えたもの
  • Medical Science Digest 42(9): 23-6
  • 久保直樹、白根健次郎、佐々木裕之
  • 生殖細胞におけるエピゲノムのダイナミズム
  • 実験医学増刊 34(10):エピゲノム研究 修飾の全体像の理解から先制・個別化医療へ: 51-5
  • 古賀祐一郎、岡本 勇
  • 非小細胞肺癌の治療
  • 呼吸器疾患最新治療2016-2018: 388-92
  • 坂田晋也、岡本 勇、中西洋一
  • 呼吸器疾患:肺癌
  • 診療ガイドラインUP-TO-DATE 2016-2017: 99-104

学会発表

Keystone Symposia: Immunity in Skin Development, Homeostasis and Disease
Roles of leukotriene B4 receptor type 2 in skin barrier function and wound healing.
石井由美子
Experimental Biology 2016
Leukotriene B4 receptor type 2 (BLT2) enhances skin barrier function by regulating tight junction proteins.
石井由美子
American Thoracic Society 2016
Azithromycin suppresses TGF-b-induced myofibroblast differentiation by promoting Nox4 degradation.
坪内和哉
4th Immuno-Oncology Summit
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.
井上博之
第56回日本呼吸器学会学術講演会
International Symposium
Highly sensitive detection of EGFR mutations in non-small cell lung cancer.
岩間映二
会長特別企画
症例を臨床から分子レベルまで考える6「間質性肺炎」
濵田直樹
ランチョンセミナー
ALK融合遺伝子陽性肺癌の治療戦略
岡本勇
シンポジウム
肺癌免疫治療update「免疫チェックポイント阻害剤使用における患者選択」
岡本勇
第105回日本病理学会総会
ランチョンセミナー
進行非小細胞肺癌の分子標的治療新時代
岡本勇
第20回日本がん分子標的治療学会学術集会
ワークショップ
進行非小細胞肺癌における癌幹細胞を標的とした治療開発
河野裕子
第14回日本臨床腫瘍学会学術集会
メデイカルセミナー
第3世代EGFRチロシンキナーゼ阻害剤による新たな治療戦略
岡本勇
International symposium
Japanese real-world clinical practice for EGFR-mutation positive advanced non-small-cell lung cancer.
岡本勇
ミニシンポジウム
進行非小細胞肺癌における分子標的治療薬を用いた併用療法の現状
岡本勇
パネルデイスカッション
免疫チェックポイント阻害剤による免疫関連有害事象
岡本勇
第77回日本呼吸器学会・日本結核病学会・日本サルコイドーシス/肉芽腫性疾患学会 九州支部 夏季学術講演会
学術奨励賞受賞講演
非小細胞肺癌におけるPD-L1発現のEML4-ALK融合タンパクおよびその下流シグナル経路による制御
大田恵一